Gerelma V. Andrenova

Gerelma V. Andrenova

Auto-generated profile, based on publicly available information

Gerelma V. Andrenova

Moscow City Clinical Hospital 52

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2023 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
ARA A Roppelt
A A Roppelt
MLM S Lebedkina
M S Lebedkina
ACA A Chernov
A A Chernov
TKT S Kruglova
T S Kruglova
OMO A Mukhina
O A Mukhina
DFD S Fomina
D S Fomina
Background. Primary immunodeficiencies (PIDs), now known as inborn errors of immunity, are a group of inherited diseases caused by defects in the genes that control the immune response. Patients with PIDs have risks of developing a severe course and/or death in COVID-19. Passive immunization with long-acting monoclonal antibodies (MABs) to SARS-CoV-2 should be considered as pre-exposure prophylaxis in patients with PIDs. Tixagevimab/cilgavimab is a combination of MABs that bind to the SARS-CoV-2 spike protein. Aim. To evaluate the efficacy and safety of pre-exposure prophylaxis of new SARS-CoV-2 infection in PIDs with the combination of tixagevimab/cilgavimab. Materials and methods. Forty eight patients diagnosed with PIDs were included in the study. Median follow-up after drug administration was 174 days. The total number of confirmed coronavirus infections in patients with PIDs as well as 6 months before and after administration of MAT were assessed. Results. In the analyzed cohort, the overall incidence of COVID-19 from pandemic onset to MABs administration was 75% (36/48), with 31% (11/36) of over-infected patients having had the infection more than once. The incidence of COVID-19 immediately 6 months before the introduction of tixagevimab/cilgavimab was 40%. All patients who had COVID-19 after pre-exposure prophylaxis had a mild infection. The incidence of COVID-19 6 months after tixagevimab/cilgavimab administration significantly decreased compared to the incidence 6 months before administration (7 and 40%, respectively; p0.001). Conclusion. The use of tixagevimab/cilgavimab in patients with PIDs is effective as pre-exposure prophylaxis and reduces the risk of severe COVID-19.

20 September 2023 in PULMONOLOGIYA
Verified
Journal Article
Open access
PDF file
DFD. S. Fomina
D. S. Fomina
SAS. S. Andreev
S. S. Andreev
GAG. V. Andrenova
G. V. Andrenova
TKT. S. Kruglova
T. S. Kruglova
DDD. M. Demidchik
D. M. Demidchik
MSM. Yu. Samsonov
M. Yu. Samsonov
The COronaVIrus Disease 2019 (COVID-19) is a common infectious disease characterized by hyperactivation of the immune response and the development of a “cytokine storm” upon progression. The aim of this study was to obtain additional information about the efficacy of the drug olokizumab in comparison with the Janus kinase inhibitor upadacitinib in real clinical practice in patients with mild to moderate COVID-19 and combined risk factors for disease progression. Methods. A single-center, non-interventional, prospective study was conducted in specialized day hospital patients (n = 125) who received therapy with olokizumab (n = 62) (64 mg once intravenously) and the Janus kinase inhibitor upadacitinib (n = 63) (orally, according to selected dosing regimen). The primary endpoint was the frequency of hospitalizations in the 24-hour hospital over the entire observation period. We also analyzed the frequencies of intensive care unit (ICU) transfer, prescription of respyratory therapy, use of “rescue” therapy (monoclonal antibodies/therapeutic proteins acting on interleukins (IL) and their receptors: IL-6 receptor inhibitors and Janus kinase inhibitors (baricitinib, tofacitinib, upadacitinib, etc.)), mortality, dynamics of laboratory and instrumental parameters, as well as frequency of negative and positive changes according to the clinical progression scale of the World Health Organization. Results. All study subjects showed rapid clinical improvement and recovery. Patients in both groups did not experience any negative clinical events, such as admission to a 24-hour hospital, prescription of respyratory therapy, use of “rescue” therapy, etc. Thus, the hyperinflammatory reaction and adverse clinical outcomes are effectively prevented by the timely use of both drugs. Those who received olokizumab had slightly higher levels of C-reactive protein (CRP) at baseline than those who received upadacitinib (p < 0.001). The median CRP value returned to normal on the 4th day in both groups. Patients treated with olokizumab showed a more pronounced change in CRP levels relative to baseline values. A similar trend was also established in body temperature. Conclusion. The study confirmed that early administration of olokizumab in patients with mild to moderate COVID-19 with several risk factors for the severe course is as effective a method of preemptive anti-inflammatory therapy as the use of Janus kinase inhibitors but more stronger suppression of markers and symptoms of intoxication.

23 July 2025 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
Mojca Bizjak-SuranMojca Bizjak-Suran
Mojca Bizjak-Suran
DFDaria Fomina
Daria Fomina
JPJonny Peter
Jonny Peter
AGAna M. M Giménez-Arnau
Ana M. M Giménez-Arnau
DPDavid Pesqué
David Pesqué
DTDorothea Terhorst‐Molawi
Dorothea Terhorst‐Molawi

16 June 2024 in Russian Journal of Allergy
Verified
Journal Article
Open access
PDF file
ARAnna A. Roppelt
Anna A. Roppelt
UMUlyana A. Mаrkina
Ulyana A. Mаrkina
EBElena N. Bobrikova
Elena N. Bobrikova
TКTatiana S. Кruglova
Tatiana S. Кruglova
OМOlga A. Мukhina
Olga A. Мukhina
DFDaria S. Fomina
Daria S. Fomina
BACKGROUND: Diagnosis and treatment of COVID-19 in patients with primary immunodeficiency, or inborn errors of immunity, are often challenging. AIM: Description of the COVID-19 course and therapy of adult patients with primary immunodeficiency treated in medical organizations of Moscow Healthcare Department. MATERIALS AND METHODS: We analyzed a cohort of 68 patients over 18 years (median ― 35 years) with primary immunodeficiency; 91% of patients have primary immunodeficiency with predominantly antibody deficiencies. Altogether 90 cases of the new СOVID-19 were analyzed: in 68 cases infection occurred for the first time, in 22 cases it recurred. The duration of the disease ranged from 3 to 80 days. Duration of PCR-positivity ranged from 0 to 59 days, median 8 days. RESULTS: Patients with Wuhan and Delta strains had more severe inflammatory signs according to C-reactive protein and lactate dehydrogenase, in patients with Wuhan lung involvement on CT-scam was larger. In demonstrated group of patients higher C-reactive protein correlated with larger lung involvement, longer duration of the disease and PCR-positivity, significant lymphopenia also correlated with higher C-reactive protein. To our data regularity of intravenous immunoglobulin therapy and IgG trough level didn’t correlate with infection severity and duration of the disease and virus-carriage. Indirectly, the change in the spectrum of medicine used in patients of the analyzed group coincided with the virus strain evolution. Anti-inflammatory therapy was mainly presented by dexamethasone and antagonists to interleukin 6 or its receptor (anti-IL-6): 55% and 73% for Wuhan, 63% and 50% for Delta, 17% and 39% for Omicron. Then, preference was gradually given to the target anti-cytokine medicine. Etiotropic antiviral therapy was more often used to treat infection caused by Wuhan and Delta strains ― 32% and 38%, respectively (in 17% for Omicron). With shifting toward immunotherapy by specific against COVID-19 immunoglobulins and monoclonal antibody to SARS-CoV-2: 5% and 9% for Wuhan, 0% and 75% for Delta, 48% and 83% for Omicron, respectively. Immune and etiotropic therapy was not carried out in Wuhan in 39%, in Delta in 43%, in Omicron in 41% of cases. The overall mortality rate from COVID-19 in the analyzed group was 3%. CONCLUSION: Patients with primary immunodeficiency represent a vulnerable group to the SARS-CoV-2 virus with a high risk of not only severe, but also a protracted and undulating course of infection, what must be taken into account for the correct interpretation of the patient's condition and the timely administration of the appropriate therapy.

3 June 2025 in Russian Journal of Allergy
Verified
Journal Article
Open access
PDF file
DFDarya S. Fomina
Darya S. Fomina
MLMarina S. Lebedkina
Marina S. Lebedkina
ENEkaterina A. Nikitina
Ekaterina A. Nikitina
EKElena V. Kovalkova
Elena V. Kovalkova
GAGerelma V. Andrenova
Gerelma V. Andrenova
MLMaryana A. Lysenko
Maryana A. Lysenko
BACKGROUND: ASIA is an autoimmune/inflammatory syndrome induced by adjuvants. Symptoms can be diverse, and the recurrent angioedema is one of the dominant manifestations. Genetic screening is discussed as a preventive option. The following alleles of genes: HLA type II (DRB1*0301 or in combination with HLA-B*08, DRB1*01, and DRB4), as well as Arg620Trp polymorphism in the PTPN22 gene are discussed as a cause of autoimmune diseases, including ASIA syndrome. AIM: To identify the presence of causative genetic factors in patients with ASIA syndrome by genetic screening, to identify adjuvants acting as a trigger, and to evaluate the efficacy of current therapy. MATERIALS AND METHODS: A single center observational study of 16 patients with ASIA syndrome and 10 controls was performed. Genetic screening was performed in 14 patients from the ASIA group and 10 patients from the control group. Further inclusion of patients in the study is planned. RESULTS: All patients with ASIA were women, potential triggers included hyaluronic acid fillers 10/16 (62.5 %), including in combination with breast silicone implants 1/16 (6.25 %), arthroplasty with shoulder joint replacement 1/16 (6.25 %), face hyaluronic acid injections 5/16 (31.25 %), and calcium hydroxyapatite 1/16 (6.25 %). The main site of angioedema was the face 15/16 (93.75 %), also larynx (1/16 (6.25 %)), upper (2/16) and lower extremities (1/16 (6,25 %)). Other symptoms included arthralgia, myalgia, muscle weakness — 1/16 (6.25%), hypocomplementemic urticarial vasculitis, lymphocytic colitis — 1/16 (6.25 %), arthralgia combined with lymphadenopathy — 1/16 (6.25 %), chronic spontaneous and solar urticaria — 1/16 (6.25 %), fixed erythema of the shoulder skin with fever, antiphospholipid syndrome — 1/16 (6.25 %), normocomplementemic urticarial vasculitis — 1/16 (6.25 %), Still’s disease — 1/16 (6.25 %). Autoimmune response was represented by autoantibodies in 10 (62.5 %) of 16 patients. Ten (62.5 %) patients received non-sedative antihistamines at standard and escalated doses (5 as monotherapy, 1 in combination with filler removal, 1 with hydroxychloroquine, 3 with hydroxychloroquine and omalizumab), 1 (6.25 %) received tranexamic acid, 1 (6.25 %) with danazol, 1 (6.25 %) with hydroxychloroquine, and 3 (18.75 %) patients received no therapy. A combination of two genetic factors was detected in 3 (21.4 %) patients: DRB1*0301, B1*08 (in 2 patients additionally Arg620Trp polymorphism). Isolated Arg620Trp polymorphism was detected in 6 (42.8 %) patients. CONCLUSION: Genetic factors increasing the risk of autoimmune conditions were found in 9 out of 16 patients. No genetic abnormalities were found in the control group. More than half of the patients with ASIA syndrome had genetic factors associated with autoimmunity. Further studies are needed to create reliable diagnostic and treatment algorithms.

15 April 2024 in Russian Journal of Allergy
Verified
Journal Article
Open access
PDF file
MLMarina S. Lebedkina
Marina S. Lebedkina
GAGerelma V. Andrenova
Gerelma V. Andrenova
ACAnton A. Chernov
Anton A. Chernov
ADAlexander Dushkin
Alexander Dushkin
ENEkaterina A. Nikitina
Ekaterina A. Nikitina
DFDaria S. Fomina
Daria S. Fomina
BACKGROUND: Cold urticaria is characterized by hives and/or angioedema and/or systemic reactions in response to a cold stimulus. Typical and atypical forms cold urticariahave distinguished features. Currently there is limited data in the literature on patients with isolated cold urticaria, as well as with typical and atypical forms. AIM: To analyze a cohort of patients with isolated cold urticaria and the characteristics of patients with typical and atypical cold urticaria. MATERIALS AND METHODS: We conducted a study of 89 patients with a verified diagnosis of cold urticaria, who underwent provocative testing (ice cube, TempTest). In case of a positive result, typical cold urticaria was diagnosed (n=38), negative ― atypical (n=51). The typical cold urticaria group was divided into 2 subgroups ― low threshold (17 degrees or less), high threshold (above 17 degrees). Correlations between characteristics in the subgroups were analyzed. Mathematical and statistical processing of the data was performed using the SPSS software package (version 22). Kraskell–Wallis and Dunn's criteria were used. For quantitative and categorical variables, dependence was assessed using Spearman correlation. RESULTS: The predominance of female gender, young age of disease onset, high prevalence of angioedema, high incidence of cold anaphylaxis, and atopy are noted in patients with cold urticaria. Most patients are on therapy with standard doses of antihistamines. Patients with atypical cold urticaria were younger (p=0.012), had earlier cold urticaria onset (p=0.003), lower basophil (p 0.001) and higher eosinophil counts (p=0.007). In the high temperature group, atypical cold urticaria was found to correlate with bronchial asthma (r=0.69; p 0.001) and the need to escalate the dose of antihistamines (r=0.4; p=0.03). It was also revealed that patients with cold anaphylaxis had lower scores on the Urticaria Control Test questionnaire (r=-0.46; p=0.03). At the same time, higher scores correlated in this group with the duration of the disease (r=0.66; p=0.001). In the low temperature threshold group, threshold correlates with female gender (r=-0.68; p=0.003), autoimmune diseases (r=0.51; p=0.043). Cold anaphylaxis correlates with angioedema (r=0.65; p=0.006) and autoimmune diseases (r=0.75; p=0.001). CONCLUSION: Cold anaphylaxis is a significant problem, especially in countries with cold climates. There are a number of factors that distinguish typical cold urticaria from atypical cold urticaria. Further research is needed on cold urticaria and the associated factors.